Key Takeaways COR raised FY25 EPS outlook to $15.85-$16.00 after 19.8% Q3 EPS growth and 8.7% revenue gain.COR's U.S. Healthcare Solutions and GLP-1 drug demand drive double-digit top and bottom-line growth.COR faces margin pressure from low-margin drugs and stiff competition in specialty and biosimilars.Cencora, Inc. (COR) is well-poised for growth on the back of a robust U.S. Healthcare Solutions business and product launches. However, intense competition is a concern.Shares of this Zacks Rank #3 (Hold) c ...